News

1 to 9 of 82 results

Type 2 diabetes market to increase to $47 billion in 2023

Type 2 diabetes market to increase to $47 billion in 2023

19-09-2014

As physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes…

BiosimilarsBoehringer IngelheimDiabetesEli LillyEuropeGlaxoSmithKlineInsulin Glargine [rDNA origin] InjectionJapanMarkets & MarketingNovo NordiskPharmaceuticalPricingTanzeumTrulicityUSAVictoza

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

Tentative FDA approval for Lilly and Boehringer Ingelheim's Basaglar

19-08-2014

The US Food and Drug Administration yesterday granted tentative approval for Basaglar (insulin glargine…

AbasriaBasaglarBiosimilarsBoehringer IngelheimDiabetesEli LillyInsulin Glargine [rDNA origin] InjectionLantusPharmaceuticalRegulationUSA

ADA 2014: Investigational new insulin glargine from Lilly and Boehringer comparable to Lantus

ADA 2014: Investigational new insulin glargine from Lilly and Boehringer comparable to Lantus

15-06-2014

For the first time, US pharma major Eli Lilly and family-owned German major Boehringer Ingelheim presented…

BiosimilarsBoehringer IngelheimDiabetesEli LillyInsulin Glargine [rDNA origin] InjectionLantusLY2963016PharmaceuticalResearchSanofi

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

Merck and Samsung Bioepis expand collaboration to insulin glargine candidate

11-02-2014

US pharma giant Merck & Co and South Korea’s Samsung Bioepis have expanded their collaboration with…

BiosimilarsDiabetesInsulin Glargine [rDNA origin] InjectionLantusLicensingMerck & CoPharmaceuticalResearchSamsung BioepisSanofi

1 to 9 of 82 results

COMPANY SPOTLIGHT

Menarini

Back to top